Orthofix Medical Inc. (NASDAQ:OFIX - Get Free Report) insider Patrick Fisher sold 1,295 shares of the company's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $10.09, for a total transaction of $13,066.55. Following the completion of the transaction, the insider owned 51,219 shares of the company's stock, valued at $516,799.71. This trade represents a 2.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Orthofix Medical Stock Down 4.5%

Shares of NASDAQ:OFIX traded down $0.47 during midday trading on Thursday, reaching $10.01. 225,284 shares of the company were exchanged, compared to its average volume of 336,802. Orthofix Medical Inc. has a fifty-two week low of $8.85 and a fifty-two week high of $16.99. The company has a quick ratio of 1.67, a current ratio of 2.84 and a debt-to-equity ratio of 0.55. The stock has a fifty day simple moving average of $10.59 and a two-hundred day simple moving average of $11.52. The firm has a market cap of $407.71 million, a PE ratio of -6.50 and a beta of 0.68.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last announced its earnings results on Wednesday, August 5th. The medical device company reported ($0.39) earnings per share for the quarter, topping analysts' consensus estimates of ($0.41) by $0.02. Orthofix Medical had a negative net margin of 7.41% and a negative return on equity of 14.05%. The firm had revenue of $210.93 million during the quarter, compared to analyst estimates of $209.28 million. As a group, sell-side analysts forecast that Orthofix Medical Inc. will post -1.29 earnings per share for the current year.

Institutional Trading of Orthofix Medical

A number of hedge funds and other institutional investors have recently modified their holdings of OFIX. Moore Capital Management LP bought a new stake in Orthofix Medical during the second quarter worth about $781,000. Empowered Funds LLC bought a new position in Orthofix Medical in the second quarter valued at approximately $321,000. Public Employees Retirement System of Ohio bought a new position in Orthofix Medical in the second quarter valued at approximately $348,000. Bank of America Corp DE acquired a new position in shares of Orthofix Medical during the 2nd quarter worth approximately $2,667,000. Finally, Legal & General Group Plc acquired a new position in shares of Orthofix Medical during the 2nd quarter worth approximately $37,000. Institutional investors and hedge funds own 89.76% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on OFIX shares. Barrington Research lifted their target price on Orthofix Medical from $15.00 to $17.00 and gave the company an "outperform" rating in a research report on Monday, July 6th. Wall Street Zen downgraded Orthofix Medical from a "buy" rating to a "hold" rating in a research report on Saturday, May 2nd. Canaccord Genuity Group decreased their price target on shares of Orthofix Medical from $18.00 to $13.00 and set a "buy" rating for the company in a research note on Monday, August 10th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Orthofix Medical in a report on Friday, July 17th. Finally, TD Cowen reissued a "hold" rating on shares of Orthofix Medical in a research report on Thursday, May 21st. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Orthofix Medical has an average rating of "Hold" and an average price target of $14.75.

Read Our Latest Research Report on OFIX

Orthofix Medical Company Profile

(Get Free Report)

Orthofix Medical Inc NASDAQ: OFIX is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company's core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix's product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.

Read More

• Five stocks we like better than Orthofix Medical
• 3 Energy Stocks Raising Dividends as the Sector Surges
• 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
• Walmart's Post-Earnings Drop Could Be a Buying Opportunity
• The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Orthofix Medical Right Now?

Before you consider Orthofix Medical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orthofix Medical wasn't on the list.

While Orthofix Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here